CMB ASX Chart
Snapshot
Cambium Bio Limited (CMB, formerly Regeneus Ltd), is a Sydney-based clinical-stage regenerative medicine company focusing on the development of biologics for ophthalmology and tissue repair applications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes.
Share Price Activity (ASX)
| Last (Price) | |
| Change | 0.00 (0.00) |
| Bid / Ask | - |
| Volume | |
| Volume (4w avg) | |
| Turnover | |
| Open | |
| Day Range | - |
| VWAP | |
| Prev Close | |
| Last Trade |
Performance
| 1 Week | |
| 1 Month | |
| 2024 YTD | |
| 1 Year | |
| vs Sector (1yr) | - |
| vs ASX 200 (1yr) | -24.44% |
Size
|
Market Cap
Excludes mandatory escrowed shares and foreign shares.
|
|
| ASX Rank | 2,053 of 2,357 |
| Sector Rank | 201 of 230 |
Announcements
Corporate Overview
Corporate Details
| Head Office | Paddington NSW 2021 |
| Website | www.cambium.bio |
| Registry | - |
| Auditor | Stantons International Audit and Consulting Pty Ltd |
| Date Listed | 19 Sep 2013 |
Upcoming Calendar (Forecasted)
| Date | Event |
|---|---|
| 29/08/2025 | Report (Prelim) |
| 29/08/2025 | Report (Annual) |
Former Company Names
- Regeneus Ltd (RGS), 10/04/2024
Sponsored Financial Content
Dividend History
DPS and Yield calculations use the Pay Date.
See Upcoming Dividends for all ASX companies.
Directors & Management
Directors
Management
Director Transactions
CMB directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
Director Interests
The current holdings of CMB directors.
Shareholder Info
Substantial Shareholders
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
Note: If a substantial shareholder's stake drops below 5%, the "Shareholders Selling" field shows full ownership as sold and sets "New %" to zero, even if they continue to hold shares under the limit.
| Name | Last Notice | Total Shares | Shares Held (%) |
|---|---|---|---|
| Apex Metro Investments Limited | 19/08/2024 | 691,580 | 0.06 |
| Treasure Century Group Limited | 19/08/2024 | 999,002 | 0.08 |
| Cyntec Co Ltd | 19/08/2024 | 2,384,359 | 0.20 |
| Zheng Yang Biomedical Technology Co Ltd | 19/08/2024 | 2,688,506 | 0.23 |
Shareholders Buying
12 month transaction history compiled from ASX announcements.
| Date | Name | Bought | Previous % | New % |
|---|---|---|---|---|
| 28-06-24 | Cyntec Co Ltd | 175,469,372 | 8.20 | 19.99 |
| 10-04-24 | Zheng Yang Biomedical Technology Co Ltd | 93,381,212 | -- | 12.20 |
| 10-04-24 | Cyntec Co Ltd | 62,966,489 | -- | 8.20 |
| 05-04-24 | Apex Metro Investments Limited | 69,157,904 | -- | 11.30 |
| 05-04-24 | Treasure Century Group Limited | 99,900,109 | -- | 16.30 |
Shareholders Selling
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
Historical Data
Share Price History
| Date | Close | Change | %Chg | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
Historical Data
| Year | Closing Price | Last Trade |
|---|---|---|
| 2024 | $0.005 | 28 June |
| 2023 | $0.007 | 30 June |
| 2022 | $0.061 | 30 June |
| 2021 | $0.074 | 30 June |
| 2020 | $0.07 | 30 June |
| 2019 | $0.085 | 28 June |
| 2018 | $0.12 | 29 June |
| 2017 | $0.115 | 30 June |
| 2016 | $0.125 | 30 June |
| 2015 | $0.15 | 30 June |
| 2014 | $0.39 | 30 June |
Important note:
All year-end and CSV data is "as traded on the day" and ignores corporate actions (e.g. share splits)
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.